Getinge (OM:GETI B) - Stock Price, News & Analysis

Resumen acción GETI B

Getinge AB (publ) ofrece productos y soluciones para quirófanos, unidades de cuidados intensivos y departamentos de esterilización.

Acerca de la empresa

GETI B fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	2/6
Past Performance	2/6
Financial Health	6/6
Dividends	4/6

Recompensas

Cotiza un 30.7% por debajo de nuestra estimación de su valor razonable

Se prevé un crecimiento anual de los beneficios de 13.18%

Trading a buen valor en comparación con empresas similares e industria

Análisis de riesgos

Historial de dividendos inestable

Competidores de Getinge AB (publ)

Elekta

OM:EKTA B

kr29.5b

Arjo

OM:ARJO B

kr14.2b

CellaVision

OM:CEVI

kr5.3b

Elos Medtech

OM:ELOS B

kr5.7b

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Getinge
Historical stock prices
Current Share Price	kr209.70
52 Week High	kr275.20
52 Week Low	kr174.20
Beta	0.56
1 Month Change	-1.60%
3 Month Change	-7.95%
1 Year Change	-18.85%
3 Year Change	-21.58%
5 Year Change	80.00%
Change since IPO	499.14%

Noticias y actualizaciones recientes

The Getinge AB (publ) (STO:GETI B) Annual Results Are Out And Analysts Have Published New Forecasts

Mar 30

Getinge's (STO:GETI B) Upcoming Dividend Will Be Larger Than Last Year's

Mar 29

The Return Trends At Getinge (STO:GETI B) Look Promising

Mar 21

Recent updates

The Getinge AB (publ) (STO:GETI B) Annual Results Are Out And Analysts Have Published New Forecasts

Mar 30

Getinge's (STO:GETI B) Upcoming Dividend Will Be Larger Than Last Year's

Mar 29

The Return Trends At Getinge (STO:GETI B) Look Promising

Mar 21

Analysts Are Updating Their Getinge AB (publ) (STO:GETI B) Estimates After Its Full-Year Results

Feb 04

There's Reason For Concern Over Getinge AB (publ)'s (STO:GETI B) Price

Jan 20

Here's Why Getinge (STO:GETI B) Can Manage Its Debt Responsibly

Jan 05

Getinge AB (publ)'s (STO:GETI B) Intrinsic Value Is Potentially 42% Above Its Share Price

Dec 20

Returns On Capital Are Showing Encouraging Signs At Getinge (STO:GETI B)

Dec 05

Getinge (STO:GETI B) Has A Pretty Healthy Balance Sheet

Oct 06

Is There An Opportunity With Getinge AB (publ)'s (STO:GETI B) 37% Undervaluation?

Sep 21

Getinge's (STO:GETI B) Returns On Capital Are Heading Higher

Sep 03

Is Getinge (STO:GETI B) A Risky Investment?

Jun 28

Is There An Opportunity With Getinge AB (publ)'s (STO:GETI B) 23% Undervaluation?

Jun 15

Investors Will Want Getinge's (STO:GETI B) Growth In ROCE To Persist

Jun 01

At kr252, Is Getinge AB (publ) (STO:GETI B) Worth Looking At Closely?

May 05

Getinge (STO:GETI B) Has Announced That It Will Be Increasing Its Dividend To SEK4.25

Apr 05

Slowing Rates Of Return At Getinge (STO:GETI B) Leave Little Room For Excitement

Feb 28

Rentabilidad de los accionistas

	GETI B	SE Medical Equipment	Mercado SE
7D	-0.3%	-0.4%	-0.9%
1Y	-18.8%	-9.6%	8.2%

Rentabilidad frente al sector: GETI B obtuvo unos resultados inferiores a los del sector Swedish Medical Equipment , que el año pasado arrojó un rendimiento del -2.4%.

Rentabilidad vs. Mercado: GETI B obtuvo unos resultados inferiores a los del mercado Swedish, que fue del 2.5% el año pasado.

Volatilidad de los precios

Is GETI B's price volatile compared to industry and market?
GETI B volatility
GETI B Average Weekly Movement	4.6%
Medical Equipment Industry Average Movement	7.4%
Market Average Movement	6.0%
10% most volatile stocks in SE Market	13.1%
10% least volatile stocks in SE Market	3.4%

Precio estable de las acciones: GETI B no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de GETI B (4%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1904	11,739	Mattias Perjos	www.getinge.com

Getinge AB (publ) ofrece productos y soluciones para quirófanos, unidades de cuidados intensivos y departamentos de esterilización. La empresa opera a través de los segmentos Acute Care Therapies, Life Science y Surgical Workflows. Ofrece oxigenación por membrana extracorpórea, ventilación mecánica, asistencia circulatoria mecánica, monitorización avanzada de pacientes, equipos de infraestructura para UCI, gestión del flujo de pacientes y soluciones de drenaje.

Resumen de fundamentos de Getinge AB (publ)

¿Cómo se comparan los beneficios e ingresos de Getinge con su capitalización de mercado?
Estadísticas fundamentales de GETI B
Capitalización bursátil	kr57.12b
Beneficios(TTM)	kr2.41b
Ingresos (TTM)	kr31.83b

23.7x

Ratio precio-beneficio (PE)

1.8x

Ratio precio-ventas (PS)

¿Está GETI B sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de GETI B
Ingresos	kr31.83b
Coste de los ingresos	kr17.33b
Beneficio bruto	kr14.50b
Otros gastos	kr12.08b
Beneficios	kr2.41b

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

Apr 22, 2024

Beneficios por acción (BPA)	8.86
Margen bruto	45.54%
Margen de beneficio neto	7.58%
Ratio deuda/patrimonio	21.7%

¿Cómo se ha desempeñado GETI B a largo plazo?

Ver rendimiento histórico y comparativa

Dividendos

2.1%

Rentabilidad actual por dividendo

50%

Ratio de pagos

¿Paga GETI B dividendos fiables?

Ver historial de dividendos e índices de referencia de GETI B

¿Cuándo hay que comprar GETI B para recibir un próximo dividendo?
fechas de dividendos de Getinge
Fecha ex dividendo	Apr 23 2024
Fecha de pago de dividendos	Apr 29 2024
Días hasta ex dividendo	10 days
Días hasta la fecha de pago de dividendos	16 days

¿Paga GETI B dividendos fiables?

Ver historial de dividendos e índices de referencia de GETI B

Resumen acción GETI B

Recompensas

Análisis de riesgos

Competidores de Getinge AB (publ)

OM:EKTA B

kr29.5b

OM:ARJO B

kr14.2b

OM:CEVI

kr5.3b

OM:ELOS B

kr5.7b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

The Getinge AB (publ) (STO:GETI B) Annual Results Are Out And Analysts Have Published New Forecasts

Getinge's (STO:GETI B) Upcoming Dividend Will Be Larger Than Last Year's

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Getinge AB (publ) to Report Fiscal Year 2024 Results on Jan 28, 2025

The Return Trends At Getinge (STO:GETI B) Look Promising

Dividend increased to kr4.40

Recent updates

The Getinge AB (publ) (STO:GETI B) Annual Results Are Out And Analysts Have Published New Forecasts

Getinge's (STO:GETI B) Upcoming Dividend Will Be Larger Than Last Year's

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Getinge AB (publ) to Report Fiscal Year 2024 Results on Jan 28, 2025

The Return Trends At Getinge (STO:GETI B) Look Promising

Dividend increased to kr4.40

Getinge AB (publ) to Report Fiscal Year 2023 Final Results on Mar 27, 2024

Getinge AB (Publ) Proposes Dividend, Payable on April 29, 2024

Getinge Takes A Leap Forward in Cardiovascular Surgery with the 510(k) Clearance for Vasoview Hemopro 3

Analysts Are Updating Their Getinge AB (publ) (STO:GETI B) Estimates After Its Full-Year Results

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Getinge AB (Publ) Provides Sales Guidance for the Year 2024

Getinge Announces CFO Changes

There's Reason For Concern Over Getinge AB (publ)'s (STO:GETI B) Price

Here's Why Getinge (STO:GETI B) Can Manage Its Debt Responsibly

Price target increased by 8.4% to kr229

Getinge AB (publ)'s (STO:GETI B) Intrinsic Value Is Potentially 42% Above Its Share Price

Returns On Capital Are Showing Encouraging Signs At Getinge (STO:GETI B)

Price target increased by 7.0% to kr220

Consensus EPS estimates increase by 23%

Third quarter 2023 earnings: Revenues exceed analyst expectations

Getinge AB (publ) (OM:GETI B) acquired Healthmark Industries Company, Inc. for $320 million.

Getinge (STO:GETI B) Has A Pretty Healthy Balance Sheet

Is There An Opportunity With Getinge AB (publ)'s (STO:GETI B) 37% Undervaluation?

Getinge AB (Publ) Announces Resignation of Jeanette Hedén Carlsson as Executive Vice President Brand & Communication, Effective December 31, 2023

Getinge's (STO:GETI B) Returns On Capital Are Heading Higher

Second quarter 2023 earnings: Revenues exceed analyst expectations

Getinge Receives US FDA 510(K) Clearance for Servo-Air® Lite

Is Getinge (STO:GETI B) A Risky Investment?

Consensus EPS estimates fall by 13%

Investor sentiment deteriorates as stock falls 22%

Is There An Opportunity With Getinge AB (publ)'s (STO:GETI B) 23% Undervaluation?

Getinge AB (publ) (OM:GETI B) entered into an agreement to acquire High Purity New England Inc. for approximately $290 million.

Investors Will Want Getinge's (STO:GETI B) Growth In ROCE To Persist

At kr252, Is Getinge AB (publ) (STO:GETI B) Worth Looking At Closely?

First quarter 2023 earnings: Revenues exceed analyst expectations

Now 22% undervalued

Upcoming dividend of kr4.25 per share at 1.6% yield

Getinge (STO:GETI B) Has Announced That It Will Be Increasing Its Dividend To SEK4.25

Slowing Rates Of Return At Getinge (STO:GETI B) Leave Little Room For Excitement

Is Getinge AB (publ) (STO:GETI B) Trading At A 42% Discount?

Getinge (STO:GETI B) Is Paying Out A Larger Dividend Than Last Year

Getinge Provides Financial Guidance for the First Half, Second Half and Full Year of 2023

Is Getinge (STO:GETI B) Using Too Much Debt?

Full year 2022 earnings: EPS misses analyst expectations

Getinge AB (Publ) Proposes Dividend

Price target decreased to kr249

When Should You Buy Getinge AB (publ) (STO:GETI B)?

Price target decreased to kr272

U.S. Food and Drug Administration Broadens the Consent Decree with Getinge and Includes Its Subsidiary Datascope

Are Investors Undervaluing Getinge AB (publ) (STO:GETI B) By 49%?

Third quarter 2022 earnings: Revenues in line with analyst expectations

Getinge AB (publ) Provides Sales Guidance for the Full Year 2022

Getinge AB (Publ) Announces Executive Changes

Getinge (STO:GETI B) Has A Pretty Healthy Balance Sheet

Getinge AB (Publ) Appoints Joanna Engelke as New Executive Vice President Quality Compliance, Regulatory & Medical Affairs and Member of the Getinge Executive Team

Price target decreased to kr293

Getinge AB (Publ) Announces Medical Device Field Action of Hls Set Advanced Products

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind